NIH consensus development conference will address osteoporosis prevention, diagnosis and therapy

March 22, 2000

The National Institutes of Health (NIH) will hold a Consensus Development Conference on Osteoporosis Prevention, Diagnosis, and Therapy, March 27-29, 2000, in the main auditorium of the William H. Natcher Building on the NIH campus in Bethesda, Maryland. A news conference will conclude the 2 1/2-day meeting at 1 p.m. EST on Wednesday, March 29, 2000.

Osteoporosis is characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures-especially of the hip, spine, and wrist. About 10 million people in the United States have osteoporosis, making it the most prevalent bone disease in this country. An additional 18 million individuals in this country already have low bone mass, placing them at increased risk for this disease. Women are four times more likely than men to develop osteoporosis.

Osteoporosis once was believed to be an unavoidable consequence of aging. That view has changed in recent years, however, thanks to remarkable progress in the scientific understanding of its causes, diagnosis, and treatment. The NIH has organized this conference to help clarify the factors associated with prevention and better diagnosis and treatment of osteoporosis. The conference will bring together national and international experts in the fields of medicine, orthopedic surgery, endocrinology, rheumatology, nutrition, epidemiology, and biostatistics, as well as representatives from the public, to discuss the latest osteoporosis research findings.

After 1 1/2 days of presentations and audience discussion, an independent, non-Federal consensus panel will weigh the scientific evidence and draft a statement that will address the following key questions:The panel will present its draft statement to the public for comment at 9 a.m. on Wednesday, March 29. Following this public comment session, the panel will release its revised consensus statement at a news conference at 1 p.m. and take questions from the media.

The consensus statement is the report of an independent panel and is not a policy statement of the NIH or the Federal Government. The NIH Consensus Development Program was established in 1977 to resolve in an unbiased manner controversial topics in medicine. To date, NIH has conducted 110 such conferences addressing a wide range of controversial medical issues important to health care providers, patients, and the general public.

Additional information about this conference, including the meeting agenda, local area hotels, and directions to NIH, is available at the NIH Consensus Development Program Web site at .
NOTE TO TV EDITORS: The news conference at 1 p.m. on Wednesday, March 29 will be broadcast live via satellite on the following coordinates: Galaxy 6, Transponder 5; C-Band; Download Frequency 3800; Polarity Horizontal. (Test time 12:30 - 1:00 p.m.)

NOTE TO RADIO EDITORS: An audio report of the conference results will be available after 4 p.m. March 29, 2000 from the NIH Radio News Service by calling 1-800-MED-DIAL (1-800-633-3425).

The NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis, and Therapy will be broadcast live on the Internet by NIH Videocasting. Go to the NIH Videocast Web site -- -- any day during the conference and look for the link to the conference under "Today's Events." Viewing the videocast requires RealPlayer software, which can be downloaded from the NIH Videocast Web site.

NIH/Office of Disease Prevention

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to